Mon, Jul 28, 2014, 6:37 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Linn Energy, LLC (LINE) Message Board

wedgemahalo 465 posts  |  Last Activity: May 5, 2014 12:31 PM Member since: Jan 14, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • wedgemahalo by wedgemahalo May 5, 2014 12:31 PM Flag

    I have ben wrong on this stock for the last several months - I admit it. But the idea that they blew past earnings by such a wide margin and went down on "guidance" is absurd. This product has yet to receive anything but good news since launch - and is being used without hesitation in the oncology community. I can admit to being wrong on the stock price given how beaten down all of biotech has been this past 1-2 months - but from absolutely any fundamental stand-point this is a screaming buy.....

    Sentiment: Strong Buy

  • Buy low, sell high is very different from buy at the lowest point and sell at the highest point. You make money when you buy on these drops - particularly when the drop is related to an "industry" or "sector" trend and not related to the company and its own operations. The people selling at this level (beyond those that trade daily and weekly) will lose in the longer term....

    Sentiment: Strong Buy

  • Nothing goes straight up forever......Buy low, sell high......The people that made huge sums of money are people that had cash on hand in 2008/2009 and bought completely undervalued companies. It was like shooting fish in a barrel. Now you have an opportunity to buy this stock at a price that it was selling for when they had no approved products on the market. As for when to sell (at least a portion of any stock) when a ton of buy recommendations come in - you need to sell in the few days right after that. When too many people recommend a stock, that means it immediately gets flooded with buyers, stock gets a bump that day or so, and then drops (and those that bought at the peak get #$%$ and sell even more into the decline).

    Sentiment: Buy

  • Reply to

    What am I missing here ?

    by krazybon913 Apr 2, 2014 1:17 PM
    wedgemahalo wedgemahalo Apr 2, 2014 1:48 PM Flag

    NO worries - the drop completely coincides with the drop in biotech overall. When sales are announced , it will go up significantly. The price now is about where it was BEFORE approvals. No way to justify the current price here when it is on the market, doing well, especially with a CLL approval. Rare to get a chance at a biotech with such little downside.

    Sentiment: Buy

  • 'Nuff said.....that means potentially $8 - $10 billion the first year of launch - simply unheard of in the industry.....

    Sentiment: Buy

  • Reply to

    Another Fun Day as a PCYC Investor

    by maxcoatinc Mar 24, 2014 9:55 AM
    wedgemahalo wedgemahalo Mar 24, 2014 10:45 AM Flag

    REGN, Intercept, GILD, Celgene all down. This is a gift on low volume!!!

  • People here in the office want to know why I am smiling - and I tell them it's because I just made the easiest money ever. Loaded up on more during the last drop below $130 - was SHOCKED it happened post-approval.

    Sentiment: Buy

  • Reply to

    Classic sell the news

    by radmok Feb 12, 2014 3:56 PM
    wedgemahalo wedgemahalo Feb 16, 2014 8:46 PM Flag

    The risk is minimized now for the product. Compare this to all the products that are in development - where risk remains. With a product like this already on the market - it also raises the bar for others before approval. Sales data should be out soon - and that is prior to CLL indication, which will really see it take off. Imagine how fast this will be adopted.....

    Sentiment: Buy

  • wedgemahalo wedgemahalo Feb 14, 2014 1:51 PM Flag

    People want to see sales numbers before the next move. Given the timing of the new indication, they should be headed to the high side of sales expectations - and now well ahead of capturing the market before any reasonable competition is launched.

    Sentiment: Buy

  • Reply to

    Way too expensive above 30

    by satchyaa Nov 23, 2013 12:53 PM
    wedgemahalo wedgemahalo Jan 23, 2014 1:03 PM Flag

    People said it was way too expensive when it was single digits. The reason it trades at a high multiple now is because of the growth of Kate Spade. The expectation is another sale (IMHO). It cannot last forever - look at COach - but these stocks trade very well when brands are growing rapidly (Michael Kors). The upside comes from continued execution with the brand to attract a buyer.

    Sentiment: Hold

  • wedgemahalo by wedgemahalo Jan 22, 2014 10:56 PM Flag

    Anyone have a sense of when first set of sales data will be available?

    Sentiment: Hold

  • Reply to

    ABT-199 just did it again

    by snakeriver Jan 8, 2014 10:35 AM
    wedgemahalo wedgemahalo Jan 9, 2014 6:20 AM Flag

    People would do well to look at what happened with Gleevec when it launched - i certainly faced competition with sprycel from BMS. But first to market is of critical importance in these smaller cancer marketplaces. The patients that are currently diagnosed now have access to Imbruvica - not to Gilead's drug or Abbvie's drug. They will be put on Imbruvica and stay on it. Then Imbruvica will be standard of care, and the others will be fighting for failures. Admitedly it is oversimplified - but NCCN guidelines will first come out with Imbruvica as the recommended therapy - and it will take time to change that.

    Sentiment: Buy

  • Breaking solidly above $32 is great to see. Will not be long as more and more people find out about this stock, its dividend, and recent "counter-punching" to all the ignorant stories early last year (should be a case study in shorts manipulating a stock through media outlets when the facts show it was all b.s.)

    Sentiment: Buy

  • Go find e a better investment. This is so "under the radar" - although Mad Money may change that. SEC allows two mergers/acquisitions to go forward during an informal investigation - big deal goes through at a bit of a premium - payouts continue. Easiest "BUY" ever......

    Sentiment: Strong Buy

  • wedgemahalo wedgemahalo Dec 9, 2013 12:31 PM Flag

    Price is meaningless compared to current therapies since the results are so much better. There is no price sensitivity in cancer therapies.

    Sentiment: Strong Buy

  • Reply to

    On the Pre-ASH run up post Nov Earnings

    by doll.ellie Dec 2, 2013 12:57 PM
    wedgemahalo wedgemahalo Dec 3, 2013 7:44 AM Flag

    My plan is to hold until just prior to earnings - and then take some profits. I expect ASH and pre-earnings news/press coverage to all be positive running into the actual earnings. I think earnings will be good - but not to be able to beat very high expectations

    Sentiment: Buy

  • Reply to

    Why doesnt JNJ just buy out PCYC already?

    by crossmebaby123 Dec 2, 2013 3:19 PM
    wedgemahalo wedgemahalo Dec 3, 2013 7:42 AM Flag

    Makes complete sense - J&J already has what it wants from the deal. They make great money from it and give PCYC its cut. No one else can buy them without paying off J&J. The reason for J&J to buy is NOT ibrutinib but if they believe the rest of the pipeline is worth the purchase.

    Sentiment: Buy

  • wedgemahalo by wedgemahalo Dec 2, 2013 8:29 AM Flag

    Should be a big discussion point - can be actively promoted as well. Should give it positive momentum this week and into the early use of the product...

    Sentiment: Buy

  • Reply to

    elizebeth warren says

    by thegreatone561 Nov 21, 2013 9:51 AM
    wedgemahalo wedgemahalo Nov 22, 2013 12:22 PM Flag

    Social security was designed to reduce poverty for the elderly - and when designed it was known that less than half of those that contributed would ever receive it based on life expectancy. The program has been very successful at reducing poverty in the elderly - but now demographics have caught up to it. Warren's suggested solution changes the way the program was designed - your payout is based on what you paid in. The reason for the cap is that you are also capped on how much you can take out. I would at least consider her idea if she raised how much those that contribute more could receive in benefits - or allow the wealthy to put more in tax saving vehicles such as IRA's. Her proposal is 100% to take money from others and redistribute it (and it is redistributing from younger people to older people). She ignores, as many do, that the wealthiest demographic in the country is the elderly (those over 65). We keep discussing taxing more of younger (and less wealthy) people to fund entitlements for older (and more wealthy) people. It is absurd, but it gets votes for the Democrats plain and simple.....

    Sentiment: Buy

  • Reply to

    What on earth are our politicians doing???

    by wedgemahalo Nov 21, 2013 10:48 AM
    wedgemahalo wedgemahalo Nov 21, 2013 2:42 PM Flag

    The supply of natural gas is indeed growing - which is not bad for LINE. My comment was not about LINE or how one makes money in natural gas. It was about the seemingly idiocy of our gov't as they scratch their heads about creating jobs. If they allowed more fracking (look at recent vote in CO and Cuomo stopping it in New York) there would be more savings for Americans, more money spent, more manufacturing plants in the US. DOW and DD both are making huge investments in the US because nat gas is driving their COGS down. If we used half the money thrown at ethanol or "green" energy to expand nat gas supplies to New England (where most homes use heating oil) - we would see even more savings to consumer, companies, etc. This is going to have a bigger impact on the US economy than the internet because the US, Canada, and Australia get a disproportionate benefit from it. The Feds have only slowed it down - and there is a strong environmental case for it with already seen, measured CO2 emission reduction (versus the mainly theoretical risk of methane release and the non existent discussion of leaks of nat gas into water tables)

    Sentiment: Buy

LINE
30.96-0.21(-0.67%)Jul 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.